Podocytes express IL-6 and lipocalin 2/neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury

Nephron - Experimental Nephrology

Volumn 121, Issue 3-4, 2013, Pages

  Lee, Sarah J ^a,b   Borsting, Emily ^a   Declèves, Anne Emilie ^b   Singh, Prabhleen ^a,b   Cunard, Robyn ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acute kidney injury; Albuminuria; Glomeruli; Interleukin 6; Lipocalin; Lipopolysaccharides

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA HYBRIDIZATION; SEPSIS;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ANIMALS; CELL LINE, TRANSFORMED; CELLS, CULTURED; INTERLEUKIN-6; KIDNEY GLOMERULUS; LIPOCALINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOGENE PROTEINS; PODOCYTES;

EID: 84870766660     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000345151     Document Type: Article

References (74)

1. Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210-4221.
2. Zarjou A, Agarwal A: Sepsis and acute kidney injury. J Am Soc Nephrol 2011; 22: 999-1006.
3. Edelstein CL, Schrier R: ARF: pathogenesis, diagnosis and management; in Schrier R (ed): Renal and Electrolyte Disorders. Philadelphia, Lippincott Williams & Wilkins, 2003, vol 6, pp 401-455.
4. Laszik Z, Nadasdy T, Johnson LD, Lerner MR, Brackett D, Silva FG: Renal interleukin-1 expression during endotoxemia and gram-negative septicemia in conscious rats. Circ Shock 1994; 43: 115-121. (Pubitemid 24369705)
5. Pagtalunan ME, Olson JL, Tilney NL, Meyer TW: Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol 1999; 10: 366-373. (Pubitemid 29068077)
6. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397. (Pubitemid 39071694)
7. Basu S, Bhattacharya M, Chatterjee TK, Chaudhuri S, Todi SK, Majumdar A: Microalbuminuria: a novel biomarker of sepsis. Indian J Crit Care Med 2010; 14: 22-28.
8. Matsui K, Kamijo-Ikemori A, Hara M, Sugaya T, Kodama T, Fujitani S, Taira Y, Yasuda T, Kimura K: Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol 2011; 15: 220-225.
9. Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M, Biancone L, Triolo G, Ranieri VM, Camussi G: Circulating plasma factors induce tubular and glomerular alterations in septic burns patients. Crit Care 2008; 12:R42.
10. Kato T, Mizuno-Horikawa Y, Mizuno S: Decreases in podocin, CD2-associated protein (CD2AP) and tensin2 may be involved in albuminuria during septic acute renal failure. J Vet Med Sci 2011; 73: 1579-1584.
11. Lee DW, Faubel S, Edelstein CL: Cytokines in acute kidney injury (AKI). Clin Nephrol 2011; 76: 165-173.
12. Cunningham PN, Wang Y, Guo R, He G, Quigg RJ: Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004; 172: 2629-2635. (Pubitemid 38182415)
13. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY: Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 2005; 16: 3315-3325. (Pubitemid 46179335)
14. Fukatsu A, Matsuo S, Yuzawa Y, Miyai H, Futenma A, Kato K: Expression of interleukin 6 and major histocompatibility complex molecules in tubular epithelial cells of diseased human kidneys. Lab Invest 1993; 69: 58-67. (Pubitemid 23222247)
15. Niemir ZI, Stein H, Dworacki G, Mundel P, Koehl N, Koch B, Autschbach F, Andrassy K, Ritz E, Waldherr R, Otto HF: Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int 1997; 52: 393-403. (Pubitemid 27359582)
16. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW: Direct effects of dexamethasone on human podocytes. Kidney Int 2006; 70: 1038-1045. (Pubitemid 44344073)
17. Matsumoto T, Hess S, Kajiyama H, Sakairi T, Saleem MA, Mathieson PW, Nojima Y, Kopp JB: Proteomic analysis identifies insulin-like growth factor-binding proteinrelated protein-1 as a podocyte product. Am J Physiol Renal Physiol 2010; 299:F776-F784.
18. Niemir ZI, Stein H, Ciechanowicz A, Olejniczak P, Dworacki G, Ritz E, Waldherr R, Czekalski S: The in situ expression of interleukin-8 in the normal human kidney and in different morphological forms of glomerulonephritis. Am J Kidney Dis 2004; 43: 983-998. (Pubitemid 38691493)
19. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80. (Pubitemid 43117741)
20. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313. (Pubitemid 43159982)
21. Burt D, Salvidio G, Tarabra E, Barutta F, Pinach S, Dentelli P, Camussi G, Perin PC, Gruden G: The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am J Pathol 2007; 171: 1789-1799.
22. Morse E, Schroth J, You YH, Pizzo DP, Okada S, Ramachandrarao S, Vallon V, Sharma K, Cunard R: TRB3 is stimulated in diabetic kidneys, regulated by the ER stress marker CHOP, and is a suppressor of podocyte MCP-1. Am J Physiol Renal Physiol 2010; 299:F965-F972.
23. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365. (Pubitemid 38406974)
24. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL: Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007; 2: 22-30.
25. Mitazaki S, Kato N, Suto M, Hiraiwa K, Abe S: Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury. Toxicology 2009; 265: 115-121.
26. Song L, Schindler C: IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 2004; 177: 43-51. (Pubitemid 39361137)
27. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ, Devarajan P, Landry DW, D'Agati V, Lin CS, Barasch J: The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17: 216-222.
28. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-2543. (Pubitemid 37169339)
29. Siew ED, Ware LB, Gebretsadik T, Shintani A, Moons KG, Wickersham N, Bossert F, Ikizler TA: Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009; 20: 1823-1832.
30. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'Amico G, Goldsmith D, Devarajan P, Bellomo R: Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010; 36: 452-461.
31. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 1834-1839. (Pubitemid 43228779)
32. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36. (Pubitemid 47014453)
33. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C: A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805. (Pubitemid 34988366)
34. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
35. Morse E, Selim E, Cunard R: PPAR-ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced cyclin B1 expression. Mol Immunol 2009; 46: 3454-3461.
36. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716. (Pubitemid 36278589)
37. Opal SM: Endotoxins and other sepsis triggers. Contrib Nephrol 2010; 167: 14-24.
38. Novick D, Engelmann H, Wallach D, Leitner O, Revel M, Rubinstein M: Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr 1990; 510: 331-337. (Pubitemid 20197909)
39. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-1157. (Pubitemid 120035064)
40. Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
41. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T: Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825-828.
42. Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-236. (Pubitemid 44835496)
43. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, Himmelfarb J, Zager RA: MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22: 165-175.
44. Kelley VR, Rovin BH: Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 2003; 24: 411-421. (Pubitemid 36683397)
45. Jang HR, Ko GJ, Wasowska BA, Rabb H: The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 2009; 87: 859-864.
46. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A: Podocytes undergo phenotypic changes and express macrophagicassociated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53: 918-925. (Pubitemid 28155664)
47. Coers W, Brouwer E, Vos JT, Chand A, Huitema S, Heeringa P, Kallenberg CG, Weening JJ: Podocyte expression of MHC class I and II and intercellular adhesion molecule-(ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol 1994; 98: 279-286. (Pubitemid 24336826)
48. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM: Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302:F647-F657.
49. Schoester M, Heinrich PC, Graeve L: Regulation of interleukin-6 receptor expression by interleukin-6 in human monocytes-a reexamination. FEBS Lett 1994; 345: 131-134. (Pubitemid 24188909)
50. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH: IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19: 1106-1115.
51. Coletta I, Soldo L, Polentarutti N, Mancini F, Guglielmotti A, Pinza M, Mantovani A, Milanese C: Selective induction of MCP-1 in human mesangial cells by the IL-6/SIL-6R complex. Exp Nephrol 2000; 8: 37-43. (Pubitemid 30051352)
52. Vannay A, Fekete A, Langer R, Toth T, Sziksz E, Vasarhelyi B, Szabo AJ, Losonczy G, Adori C, Gal A, Tulassay T, Szabo A: Dehydroepiandrosterone pretreatment alters the ischaemia/reperfusion-induced VEGF, IL-1 and IL-6 gene expression in acute renal failure. Kidney Blood Press Res 2009; 32: 175-184.
53. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL: Cisplatininduced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007; 322: 8-15. (Pubitemid 46956357)
54. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C: Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 2005; 312: 1170-1178. (Pubitemid 40293778)
55. Klein CL, Hoke TS, Fang WF, Altmann CJ, Douglas IS, Faubel S: Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 2008; 74: 901-909.
56. Mitazaki S, Honma S, Suto M, Kato N, Hiraiwa K, Yoshida M, Abe S: Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors. Life Sci 2011; 88: 1142-1148.
57. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 2003; 23: 13-17. (Pubitemid 35316759)
58. Kato N, Abe S, Suto M, Hiraiwa K: Comparison of renal dysfunction in wild-type, IL-6 KO and iNOS KO mice hind limb tourniquet-reperfusion model. Leg Med (Tokyo) 2009; 11(suppl 1):S248-S251.
59. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-714. (Pubitemid 32592418)
60. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A: IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003; 4: 551-556. (Pubitemid 36701338)
61. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-413. (Pubitemid 46193306)
62. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002; 10: 1033-1043. (Pubitemid 36001971)
63. Luchtefeld M, Preuss C, Ruhle F, Bogalle EP, Sietmann A, Figura S, Muller W, Grote K, Schieffer B, Stoll M: Gp130-dependent release of acute phase proteins is linked to the activation of innate immune signaling pathways. PLoS One 2011; 6:e19427.
64. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, Ebihara K, Omata M, Satoh N, Sugawara A, Barasch J, Nakao K: Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285-294.
65. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY: Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009; 36: 45-51.
66. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M: Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32: 91-98.
67. Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P: Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011; 79: 1113-1118.
68. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P: Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006; 21: 989-994. (Pubitemid 43885099)
69. Damas JK, Baekken M, Ueland T, Manner IW, Os I, Yndestad A, Flo TH, Oktedalen O, Aukrust P: Serum levels of neutrophil gelatinase-associated lipocalin are associated with microalbuminuria in HIV-infected patients. J Acquir Immune Defic Syndr 2012; 59:e24-e25.
70. Sola-Del Valle DA, Mohan S, Cheng JT, Paragas NA, Sise ME, D'Agati VD, Barasch J: Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant 2011; 26: 2387-2390.
71. Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Reigosa JM, Lu TY, Isenberg D, Rahman A, Putterman C: Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010; 49: 960-971.
72. Rubinstein T, Pitashny M, Putterman C: The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/lipocalin-2 as a biomarker for lupus nephritis. Autoimmun Rev 2008; 7: 229-234.
73. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F: Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-4076.
74. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G: Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58: 2109-2118.